All News

Denosumab inhibiting osteolysis? 22 pts undergoing revision THR surgery for osteolysis, 10 Rx w/ denosumab had 83% fewer osteoclasts @ osteolysis membrane–bone interface. Proof concept: DEN may have osteoclast effects at implant interface https://t.co/dJ06rk0SR3

Links:

Dr. John Cush RheumNow ( View Tweet)

Results from Cohort Hip & Cohort Knee study (early symptomatic hip OA pts) finds that 1/9 went on to receive hip replacement during the 10-year follow-up. Clinical hip and Xray (ROA) OA increased over 10 yrs - ROA 19% to 49%, and clinical hip OA 27% to 43% https://t.co/AJXlkAxZiF https://t.co/PSY4ueXOsC

Links:

Dr. John Cush RheumNow ( View Tweet)
The NEJM has featured an overview of Osteoarthritis of the Knee. https://t.co/1AaNICygOr

Links:

Dr. John Cush RheumNow ( View Tweet)

Adipose Transplants as a New Regulator of Osteoarthritis--A novel report from PNAS suggests that in osteoarthritis (OA), the damage is not entirely from body weight and mechanics, instead it may be from adipose tissue itself. Read more: https://t.co/0VpR4VPmBX https://t.co/jSALMKXrhB

Links:

Dr. John Cush RheumNow ( View Tweet)
Adipose fat cells

Adipose Transplants as a New Regulator of Osteoarthritis

d Jack Cush, MD

A novel report from PNAS suggests that in osteoarthritis (OA), the damage is not entirely from body weight and mechanics, instead it may be from adipose tissue itself.

Read Article
pills.bottle.hand__0.jpg

EULAR Guidance on Patient Adherence to Meds

d Jack Cush, MD

Non-adherence may be the single most untold risk to suboptimal outcomes in the care of musculoskeletal disease.  It has been estimated that 30-80% of patients with rheumatic and musculoskeletal diseases (RMDs) are nonadherent to prescribed regimens.  EULAR has commissioned a task force

Read Article
Dr. Janet Pope ( @Janetbirdope) reviews Osteoarthritis studies presented at #ACR20. https://t.co/QMQ8DcsK0s https://t.co/W4w9BcsoCH

Links:

Dr. John Cush RheumNow ( View Tweet)
RN.podcast.resized.jpg

RheumNow Podcast – Stop These COVID Mistakes (12.11.20)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.

Read Article
#BestACR20Tweets RT @bella_mehta : Check out our work #racialdisparities in bilateral knee replacement -10 yr USA national study - ⬇️utilization in AA but NOT ⬆️complications. #ACR20 @RheumNow ABS#1633 https://t.co/zje7ntxpzA https://t.co/Cix9G10duj

Links:

Dr. John Cush RheumNow ( View Tweet)
Check out the latest from Dr. Bella Mehta ( @bella_mehta) #ACR20 Racial disparities in Bilateral Knee Arthroplasty in Osteoarthritis https://t.co/yataL7H8X4 https://t.co/xT1vCBDLyZ

Links:

Dr. John Cush RheumNow ( View Tweet)
chalkboard disparities black white

Racial disparities in Bilateral Knee Arthroplasty in Osteoarthritis

d Bella Mehta, MBBS, MS

Although arthritis-related activity, disabling work limitations, and severe pain (which are indications for TKA) disproportionately impact African American patients compared to White patients, there are marked racial disparities documented in utilization and complications in unilateral total knee arthroplasty.  

Read Article
What’s New in Knee Osteoarthritis that Matters? by Dr. Janet Pope ( @Janetbirdope) https://t.co/Ue3o8xAytV https://t.co/YaNftmH9ZN

Links:

Dr. John Cush RheumNow ( View Tweet)
Lknee.OA_.jpg

What’s new in knee osteoarthritis that matters?

d Janet Pope, MD, MPH, FRCPC

Are intra-articular steroid injections effective in symptomatic knee OA? Do they accelerate cartilage loss? Does weight less actually help? Do we have DMARDs for knee OA? Insights from 2020 ACR Convergence.

Read Article
Warfarin and End-Stage Osteoarthritis: Dr. David Liew ( @drdavidliew) #ACR20 https://t.co/hHZTL48DTI https://t.co/X4BDGBOGFq

Links:

Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets RT @MeralElRamahiMD : When do you think we are going to get a DMARD for OA? 50% or more over age 60 will have osteoarthritis, yet we are yet to discover a promising disease modifying therapy. #ACR20 @ElaineHusniMD

Dr. John Cush RheumNow ( View Tweet)

kneepain3.jpg (keep)

Warfarin and End-Stage Osteoarthritis

d David Liew, FRACP

Dr. David Liew discusses abstract #0934 - "Warfarin Use and Risk of Knee and Hip Replacements" - presented at the 2020 ACR annual meeting.

Read Article
#BestACR20Tweets RT @Janetbirdope : IA steroids for knee OA are superior to lidocaine! Clever RCT of 27 knee OA w either 40mg methylpred acetate + lidocaine vs lidocaine w social cues to exercise. Knee injury & OA outcome score superior for IA steroids in prelim data

Dr. John Cush RheumNow ( View Tweet)

Recognition and Early Treatment of MAS--Dr Olga Petryna ( @DrPetryna ) discusses two abstracts, abstract #1496 and #1149, presented at the #ACR20 annual meeting. https://t.co/Y3eymjYsgP https://t.co/qxHlmOyDLy

Links:

Dr. John Cush RheumNow ( View Tweet)
Listen to the Rheum Now podcast on Day 4 of the #ACR20 meeting. Topics: Belimumab in Lupus Nephritis, Enthesitis in PsA, Equity & Inclusion in Rheumatology Education, Osteoarthritis Studies, Outcomes of COVID in Rheumatic Disease Patients https://t.co/1PShHqXa0j https://t.co/9ALWsjWqpB

Links:

Dr. John Cush RheumNow ( View Tweet)
Roundup RHeum ACR

Rheumatology Round-Up with Drs. Kavanaugh & Cush

d Jack Cush, MD

The Annual Review of Best ACR 2020 abstracts featuring Drs. Cush and Kavanaugh filmed on the last day of Virtual ACR 2020 Nov. 9, 2020. Watch now!


Read Article

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.